Stay updated on Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial

Sign up to get notified when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the webpage content.
    Difference
    0.3%
    Check dated 2024-06-13T22:26:45.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in medical or healthcare-related publications or documentation.
    Difference
    0.3%
    Check dated 2024-06-06T14:37:33.000Z thumbnail image
  7. Check
    17 days ago
    Change Detected
    Summary
    The value 04 16 has been updated to 05 29 on the webpage, indicating a recent change in the information related to the Medical and healthcare-related publications and documentation.
    Difference
    0.7%
    Check dated 2024-05-30T09:44:21.000Z thumbnail image
  8. Check
    24 days ago
    Change Detected
    Summary
    The value on the webpage has been updated from 6 to 7, indicating a recent change in the number of relevant medical or healthcare-related publications or documentation. This change may reflect new data or updates in clinical study records or related information.
    Difference
    0.3%
    Check dated 2024-05-22T21:35:37.000Z thumbnail image
  9. Check
    46 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T22:49:14.000Z thumbnail image

Stay in the know with updates to Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Flotetuzumab in Relapsed AML/MDS Post Allo-HCT Clinical Trial page.